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Introduction: The molecular events occurring within the human
kidney during treatment of lupus nephritis (LN) are unknown. We
previously reported that the immune proﬁle of LN biopsies at ﬂare
is different between complete responders (CR) from non- re-
sponders (NR). Here, we evaluate whether the differences in renal
transcript expression after induction therapy can distinguish bi-
opsies that end in CR and NR and identify a set of markers asso-
ciated with treatment response and non-response.
Methods: The expression of 511 immune-response genes was
determined in kidney biopsies from 19 patients with proliferative
LN and 4 normal controls using Nanostring technology. Biopsies
were done at ﬂare (Bx1) and after induction therapy (Bx2). After
induction, 5 patients achieved CR, 4 patients had an NR and 10
patients achieved a PR by clinical metrics (24 hour urine protein-
uria and serum creatinine).
Results: Transcript expression was measured at Bx1 and Bx2 in all
patients and compared to normal controls. Additionally, the change
in expression from Bx1 and Bx2 was compared within each group
and between groups. Transcripts were considered differentially
expressed if they achieved both a p-value of <0.05 and at least a 1.5
fold change. From Bx1 to Bx2, transcripts that signiﬁcantly
changed in ﬂares that ended in CR included increased expression of
NCAM1 (FC-2.24, P¼0.004), and decreased expression of IL1RL1
(FC: -3.13, P¼0.001), FKBP5 (FC: -4.76, P¼0.009), FCAR (FC: -2.04,
P¼0.011), and IL17 (FC: -1.7, P¼0.018).
Transcript expression analysis in ﬂares that ended in NR iden-
tiﬁed an 11-gene signature including increased expression of IL17
(FC: 1.66, P¼0.044), IL1RAP (FC: 2.19, P¼0.001), CD5 (FC: 2.38,
P¼0.009), and decreased expression of C7 (FC:-3.45, P¼0.001),
IL28B (FC:2.77, P¼0.003), and IL12RB1 (FC: -2.38, P¼0.004).
Between ﬂare and repeat biopsy, a 10-gene signature differentiated
ﬂares that ended in NR compared to CR and included increased
expression of IL17, IL1RAP, and iNOS and decreased expression of
NCAM1, and IL28B. Furthermore, neutrophil associated transcripts
(NCF4, LTF, CSF2RB, and CSF3R) and alternative complement
pathway component transcripts (increased C3, CFB, CFD and
decreased CFI, CD55, CD59) were more abundantly expressed in NR
biopsies compared to normal and CR biopsies with increasing
expression from Bx1 to Bx2 in the NR group.
Conclusions: These data suggest that the immunologic changes that
occur in a kidney biopsy after treatment of LN are different in ﬂares
that end in CR compared to NR. Increases in NCAM1 and IL28 may
predict response to treatment while increases in IL17 may reﬂect
non-response. Additionally, persistent neutrophil inﬁltration and
alternative pathway activation may play a role in preventing
response to standard therapy. Comparing the immunologic changes
within the kidney during successful and unsuccessful treatment
may identify novel therapeutic targets for LN and biomarkers of
response and non-response.
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Introduction: Injury in glomerulonephritis may be associated with
“proteotoxicity” due to protein misfolding, and induction of
endoplasmic reticulum (ER) stress and polyubiquitination. Exam-
ples include complement-induced glomerular epithelial cell (GEC)/
podocyte injury in membranous nephropathy, and focal segmental
glomerulosclerosis (FSGS). Podocyte injury due to proteotoxicity
can also result from mutations in integral proteins, which lead to
their misfolding and accumulation. We assessed if small molecule
modulators of proteostasis or accelerated removal of misfolded
proteins by the ubiquitin-proteasome system (UPS) can ameliorate
the proteotoxicity of misfolded proteins, using GEC culture and in
vivo models of glomerular injury.
Methods:We employed 4-phenylbutyric acid (4-PBA), a compound
that can improve protein folding by increasing the strength of
intramolecular hydrophobic bonds, or lowering a protein’s free
energy state, as well as celastrol, a drug that improves folding via
increasing expression of ER and cytosolic chaperones. Moreover, to
accelerate removal of misfolded proteins by the UPS, we employed
IU1, a compound that inhibits ubiquitin-speciﬁc protease 14
(Usp14), a deubiquitinating enzyme that retards proteasomal pro-
tein degradation.
Results: In cultured GECs stimulated with tunicamycin, 4-PBA
markedly reduced ER stress, as monitored by a reduction of stim-
ulated transcriptional activity of activating transcription factor-6
and reduction of stimulated expression of the ER chaperone, BiP.
Incubation of GECs with celastrol enhanced expression of BiP, heat-
shock protein (Hsp)-70, and transcriptional activity of heat shock
factor-1, which induces cytosolic chaperones, such as Hsp70. To
address complement cytotoxicity, GECs were incubated with anti-
body and serially-increasing doses of complement. This protocol
allows for complement to induce ER stress, but with increasing
incubation time and complement dose, a portion of the cells un-
dergoes lysis. Complement-mediated lysis in GECs was attenuated
signiﬁcantly by 4-PBA and celastrol. The UPS reporter proteins,
GFPu (a cytosolic “misfolded” protein) and CD3 (an ER-associated
degradation substrate) undergo time-dependent proteasomal
degradation in GECs. The Usp14 inhibitor, IU1, accelerated
the degradation of both misfolded reporter proteins by the pro-
teasome. IU1 did not, however, affect complement-induced GEC
cytotoxicity. The -actinin-4 K256E mutant, which induces FSGS in
humans, showed enhanced ubiquitination, formed aggregates, and
disrupted ER function in cultured GECs. 4-PBA and celastrol both
reduced -actinin-4 K256E aggregation. -actinin-4 K256E transgenic
mice develop podocyte injury, proteinuria and FSGS, in association
with glomerular ER stress. Treatment of these mice with 4-PBA in
the drinking water over a 10 week period signiﬁcantly reduced
albuminuria, and glomerular expression of the proapoptotic ER
stress protein, CHOP.
Conclusions: Podocyte injury associated with protein misfolding
was reduced by compounds that can improve protein folding either
directly or via enhanced expression of chaperones. Small molecule
proteostasis regulators may represent a novel therapeutic approach
to glomerulonephritis.
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